Stocktwits on MSN
CYDY stock falls despite positive cancer study data – retail says CytoDyn is 'here to stay'
The study evaluated Leronlimab, an investigational antibody, in combination with standard therapies TAS-102 and Bevacizumab, a targeted therapy that blocks tumor growth. ・The study showed positive ...
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with ...
Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United StatesVANCOUVER, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results